Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Becton Dickinson ( (BDX) ) has shared an announcement.
On February 25, 2026, BD announced early tender results for its cash tender offers to repurchase multiple series of outstanding senior notes and debentures, alongside the pricing of these offers. The company increased the aggregate offer cap from $1.6 billion to $2.0 billion and raised the sub-cap on its 4.685% Senior Notes due 2044, after investors tendered more than the original limits, signaling strong bondholder participation and an active effort to manage and optimize its long-term debt profile.
By the early tender deadline of February 24, 2026, holders had validly tendered and not withdrawn substantial portions of nearly all targeted series, including large amounts of long-dated notes such as the 4.669% Senior Notes due 2047 and 3.700% Senior Notes due 2027. Because the aggregate purchase price of securities tendered exceeded the revised $2.0 billion cap, BD will accept its 3.794% Senior Notes due 2050 on a prorated basis, underscoring the scale of the liability management exercise and its potential to reduce interest costs and refine the company’s maturity ladder for stakeholders and creditors.
The most recent analyst rating on (BDX) stock is a Buy with a $228.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
The score is primarily driven by steady underlying business performance but moderated by leverage, weaker cash flow trends, and net margin compression. Technicals are supportive with a clear uptrend, while valuation is a notable constraint due to a high earnings multiple. Earnings-call guidance is balanced: productivity and capital returns help offset tariff and China-related headwinds.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology firm that develops, manufactures and sells medical devices, instrument systems and reagents. The company focuses on improving drug delivery, diagnostics and clinical workflows for hospitals, laboratories and health care providers worldwide, positioning it as a key player in the medical technology and life sciences markets.
Average Trading Volume: 2,248,675
Technical Sentiment Signal: Strong Buy
Current Market Cap: $51.96B
See more data about BDX stock on TipRanks’ Stock Analysis page.